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Abstract. Recent evidence suggests that secretory vesi- 
cle formation from the TGN is regulated by cytosolic 
signaling pathways involving small GTP-binding pro- 
teins, heterotrimeric G proteins, inositol phospholipid 
metabolism, and protein serine/threonine phosphoryla- 
tion. At the cell surface, protein phosphorylation and 
dephosphorylation on tyrosine residues can rapidly 
modulate cytosolic signaling pathways in response to 
extracellular stimuli and have been implicated in the in- 
ternalization and sorting of signaling receptors. To de- 
termine if phosphotyrosine metabolism might also reg- 
ulate secretory vesicle budding from the TGN, we 
treated permeabilized rat pituitary GH3 cells with in- 
hibitors of either tyrosine phosphatases or tyrosine ki- 
nases. We demonstrate that the tyrosine phosphatase 
inhibitors pervanadate and zinc potently inhibited bud- 
ding of nascent secretory vesicles. Tyrphostin A25 
(TA25) and other tyrosine kinase inhibitors also pre- 
vented secretory vesicle release, suggesting that vesicle 
formation requires both phosphatase and kinase activi- 
ties. A stimulatory peptide derived from the NH2 termi- 
nus of the small GTP-binding protein ADP ribosylation 
factor 1 (ARF1) antagonized the inhibitory effect of 
TA25, indicating that both agents influence the same 
pathway leading to secretory vesicle formation. Anti- 
phosphotyrosine immunoblotting revealed that protein 
tyrosine phosphorylation was enhanced after treatment 
with tyrosine phosphatase or kinase inhibitors. Subcel- 
lular fractionation identified several tyrosine phos- 
phorylated polypeptides of ~175, ~130, and 90-110 kD 
that were enriched in TGN-containing Golgi fractions 
and tightly membrane associated. The phosphorylation 
of these polypeptides correlated with inhibition of vesi- 
cle budding. Our results suggest that in endocrine cells, 
protein tyrosine phosphorylation and dephosphoryla- 
tion are required for secretory vesicle release from the 
TGN. 
V 
ESICULAR transport through the eukaryotic secre- 
tory pathway is a highly regulated process that re- 
quires spatial and temporal specificity (for reviews 
see references 4, 19, 51). Members of the Rab family of 
Ras-related small GTP-binding proteins appear to provide 
temporal specificity in vesicle release, docking, and fusion 
(for reviews see references 41, 44). Other small GTP-bind- 
ing proteins, ADP ribosylation factors (ARFs)  ~, also play 
a critical regulatory role in vesicular transport. ARF pro- 
teins are required in several steps of membrane traffic 
and have been shown to regulate assembly of vesicle coat 
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proteins  and maintain organelle integrity (for reviews 
see 5, 15). In addition, ARF can activate phospholipase D 
(10, 12, 31, 32),  a phenomenon that may play a central 
role in the regulation of membrane traffic through the me- 
tabolism of inositol phospholipids  (for reviews see 14, 38). 
Enzymes in  inositol  phospholipid  metabolism directly 
implicated  in  membrane trafficking in  both  yeast  and 
mammalian  cells  include  phosphatidylinositol  transfer 
protein (23, 24, 43) and phosphatidylinositol 3-kinase (for 
reviews see 14, 38, 54). Heterotrimeric GTP-binding pro- 
teins (G proteins) have also been implicated in the regula- 
tion of membrane traffic (for reviews see 6, 41) and can in- 
teract directly with ARF (13, 50). These observations raise 
the possibility  that membrane trafficking events may be 
regulated by an interconnected network of cytosolic sig- 
naling pathways reminiscent of those initiated by cell sur- 
face signaling receptors. 
In polypeptide hormone-producing cells, the packaging 
of proteins into nascent secretory vesicles  occurs in the 
TGN, a major site of protein sorting in the endomembrane 
© The Rockefeller University Press, 0021-9525/96/12/1471/13 $2.00 
The Journal of Cell Biology, Volume 135, Number 6, Part I, December 1996 1471-1483  1471 system.  We  are  investigating  the  requirements  for both 
formation of secretory vesicles from the TGN and prohor- 
mone processing in endocrine cells and have used perme- 
abilized cells (1, 11, 37, 62) derived from growth hormone 
(GH)-  and  prolactin  (Prl)-secreting  pituitary  GH3 cells 
stably expressing human prosomatostatin (proSRIF) (16). 
Recent studies from our laboratory and others suggest that 
the regulation of secretory vesicle release from the TGN is 
complex, involving ARF1 (11), rabs 6 and 8 (26, 30), het- 
erotrimeric  G  proteins  (35, 45,  and  Austin,  C.D.,  Y.-G. 
Chen, and D. Shields, unpublished observations), metabo- 
lism  of inositol  phospholipids  (43),  and  protein  serine/ 
threonine phosphorylation (30, 40, 42, 46, 63). It is unclear, 
however, how the packaging  of vesicle cargo proteins  in 
the TGN lumen could be linked to such an intricate  net- 
work  of cytosolic  regulation  during  coat  assembly  and 
budding  of  secretory  vesicles.  One  way  this  might  be 
achieved is by protein  tyrosine phosphorylation.  Protein 
tyrosine phosphorylation  is a reversible, dynamic process 
that  plays an  essential  role  in fundamental  cellular  pro- 
cesses such as growth and differentiation.  Receptor tyro- 
sine  kinases  transduce  signals  across  the  plasma  mem- 
brane  to  regulate  several  cytosolic  signaling  pathways 
involving  the  activities  of nonreceptor  tyrosine  kinases 
and  phosphatases,  small  GTP-binding  proteins  such  as 
Ras,  serine/threonine  kinases,  and  enzymes  involved  in 
inositol  phospholipid  metabolism  such  as  phosphatidyl- 
inositol 3-kinase and phospholipases C and D  (for review 
see 60). Phosphotyrosine metabolism has also been impli- 
cated in signaling  events involving heterotrimeric  G  pro- 
teins (36, 39, 55, 61). Although phosphotyrosine metabo- 
lism is believed to participate mainly in signal transduction 
pathways initiated at the cell surface, recent evidence sug- 
gests that it may also transduce signals arising intracellu- 
lady from membrane-enclosed organelles (for review see 2). 
Nascent  secretory  vesicle  formation  in  endocrine  cells 
presents an attractive target for such regulation since regu- 
lated secretion itself is signal mediated. Here we have used 
protein  tyrosine  phosphatase  and  kinase  inhibitors  to 
examine the role of phosphotyrosine metabolism in the re- 
lease of nascent secretory vesicles from the TGN of per- 
meabilized cells.  Our  data implicate  both  tyrosine phos- 
phatase and kinase activities in secretory vesicle formation 
through a signaling pathway involving the vesicle coat as- 
sembly factor ARF1. 
Materials and Methods 
Sodium orthovanadate was purchased from Fisher Scientific (Pittsburgh, 
PA). Tyrphostin A25 (TA25), tyrphostin A1 (TA1), lavendustin A (Lav A), 
genestein, okadaic acid, staurosporin, and calphostin C were purchased 
from Calbiochem-Novabiochem Corp. (La Jolla, CA). Picrylsulfonic acid 
(trinitrobenzene sulfonate [TNBS]) was purchased from Sigma Chemical 
Co. (St. Louis, MO). The 16-amino acid peptide (GNIFANLFKGLFGKKE) 
corresponding to the NH2 terminus of human ARF1 (residues 2-17) was 
synthesized in the Laboratory for Molecular Analysis (Albert Einstein 
College of Medicine). Rabbit anti-Prl serum, anti-GH serum, and anti- 
SRIF-propeptide serum, which recognizes preproSRIF, proSRIF, and the 
free propeptide  (16),  were described previously (1).  Monoclonal anti- 
phosphotyrosine antibody  (PY20)  for immunofluorescence microscopy 
and horseradish peroxidase--conjugated  recombinant antiphosphotyrosine 
antibody (HRPO-RC20) for immunoblotting were purchased from Trans- 
duction Laboratories (Lexington, KY).  Rabbit anti-TGN38  serum was 
generously provided by Sharon Milgram (University of North Carolina, 
Chapel Hill, NC) and Richard Mains (Johns Hopkins University, Balti- 
more,  MD).  Rabbit  anti-DNP  serum  was  described  previously  (22). 
Cy3a~-conjugated goat anti-rabbit IgG and FITC-conjugated goat anti- 
mouse IgG antibodies were purchased from Jackson ImmunoResearch 
Laboratories, Inc. (West Grove, PA). Rat anterior pituitary GH3 cells 
stably expressing human preproSRIF (GHa.Hu.S) were described previ- 
ously (16). 
Preparation of  Pervanadate 
10 mM sodium orthovanadate was freshly prepared and treated with 10 
mM H202 for 10 rain at room temperature just before use. Residual H202 
was removed by incubating for 5 rain at room temperature with 100 ~g/ml 
(21,000 U/mg) catalase (18, 49). For mock incubations, orthovanadate was 
omitted. 
Cell Culture and Pulse Labeling 
GH3.Hu.S cells were grown and pulse labeled as previously described (1, 
56) with 500 I~Ci [35S]methionine/ml,  which in the case of proSRIF radio- 
labels only the amino-terminal propeptide region, and chased in the pres- 
ence of complete growth medium for 2 h at 190C. These conditions result 
in retention of most of the radiolabeled hormones in the TGN (62). Cells 
were then placed at 4°C before subsequent treatment. 
Cell Surface Labeling 
Intact cells were surface labeled either before or after the 2-h 19°C chase 
as described previously (22). Briefly, cultures were chilled at 4°C, washed 
three times in PBS-T (125 mM NaCI, 25 mM NaPO4, pH 8.0), and then in- 
cubated in 10 mM TNBS in PBS-T at 4°C for 15 min. Cells were then 
washed three times in PBS-T and once in PBS-T containing I mg/ml BSA 
before subsequent treatment. 
Permeabilized Cell Preparation and In 
Vitro Incubations 
Preparation  of permeabilized cells by a  swell-scrape method was  de- 
scribed previously (1, 62). The control incubation condition for these ex- 
periments contained ~5 ×  l0  s permeabilized cells, 20 mM Hepes, pH 7.3, 
125 mM KC1, 2.5 mM MgCI:, 1 mM ATP, 200 p,M GTP, 10 mM creatinine 
phosphate, 160 p,g/ml creatinine phosphate kinase (ATP-regenerating sys- 
tem), 0.5 mM PMSF, and 5 ixg/ml trasylol. Incubation for 2 h at 37°C un- 
der these conditions is sufficient to reconstitute both proSRIF processing 
and nascent secretory vesicle release from the TGN (62).  Permeabilized 
cells were pretreated with or without the indicated concentration of inhib- 
itors for 10 min at 4°C before addition of the ATP-regenerating system 
and incubation at 37°C. The final concentration of DMSO in the reactions 
did not exceed 0.5%, which itself had no effect on proSRIF processing or 
vesicle budding. 
Immunoprecipitation and Densitometry 
The assay for nascent secretory vesicle budding was based on quantitating 
the release of radiolabeled hormones into a 15,000 g supernatant after an 
in vitro incubation (1,11, 37, 62). Processing of radiolabeled proSRIF was 
determined by quantitating the percentage of anti-SRIF-propeptide gen- 
erated from proSRIF after immunoprecipitation using the anti-SRIF pro- 
peptide antibody (16). After the incubation, permeabilized cells were pel- 
leted and lysed in detergent and the lysates and supernatants containing 
nascent secretory vesicles were treated sequentially with anti-Prl, anti-GH, 
and anti-SRIF propeptide serum as described previously (1, 56).  Immu- 
noreactive material was resolved by SDS-PAGE and detected by fluorog- 
raphy. Band intensities were quantitated using a computing densitometer 
(model 300A; Molecular Dynamics, Sunnyvale, CA) and Image Quant 3.3 
software (Molecular Dynamics). 
Immunoblotting 
Proteins were precipitated from detergent lysates at -20°C by adding 9 
vol acetone/0.1 N HCI and from 15,000 g supernatants or sucrose gradient 
fractions at 4°C by adding an equal volume of ice cold 20% (wt/vol) TCA. 
The precipitates were dissolved in SDS gel buffer by low-power micro- 
probe sonication, resolved by SDS-PAGE, and transferred to polyvinyl 
difluoride (PVDF)  membranes. Membranes were subsequently probed 
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dilution), or for TGN38 or the TNP moiety with appropriate antiserum 
(1:100 dilution) followed by horseradish peroxidase--conjugated anti-rab- 
bit IgG (secondary antibody, 1:1,000 dilution), and detected by chemilu- 
minescence (Amersham Corp., Buckinghamshire, England). 
Subcellular Fractionation 
To isolate an enriched TGN/Golgi membrane fraction after treatment of 
,,ol  ×  107 permeabilized GH3.Hu.S  cells with pervanadate, cells were 
homogenized using eight strokes of a stainless steel ball-bearing homog- 
enizer (12.7-1~m clearance) in 1.5 ml homogenization buffer (0.25  M su- 
crose, 20 mM Hepes KOH, pH 7.3, 2.5 mM MgCI2, 0.5 mM PMSF, 5 Ixg/ml 
trasylol, and 100 p.M pervanadate  ). The homogenate was adjusted to ~1.4 M 
sucrose and loaded onto a step gradient comprising 2 ml 2 M sucrose cush- 
ion overlaid with ~2 ml adjusted homogenate ("load zone"), 7 ml 1.2 M 
sucrose, and 2  ml 0.8  M  sucrose; all solutions contained 20 mM Hepes 
KOH, pH 7.3, 2.5 mM MgCI2, and 100 IxM pervanadate. The gradient was 
centrifuged for N14 h  at 35,000  rpm at 4°C in a  rotor (model SW41Ti; 
Beckman Instrs., Fullerton, CA) to float the TGN/Golgi membranes to 
equilibrium (between 1.2 M and 0.8 M sucrose, 62). Fractions (1 ml each) 
were collected from the top of the gradient and fraction aliquots were as- 
sayed for total protein by the method of Bradford (8), radiolabeled hor- 
mones by immunoprecipitation (see above), and TGN38, tyrosine-phos- 
phorylated proteins, and the TNP moiety by immunoblotting (see above). 
It was previously shown that most of the pulse-labeled GH and proSRIF- 
derived peptides from intact  cell homogenates following a  2-h N19°C 
chase cofractionated with the distal TGN/GoIgi marker enzymes galacto- 
syl and sialyl transferases and the TGN marker protein TGN-38 near the 
top of the gradient (fractions 2--4), whereas most of the total protein and 
>95% of the endoplasmic reticulum marker ribophorin I remained in the 
load zone (62). 
Immunofluorescence Microscopy 
After appropriate treatments, permeabilized cells were sedimented briefly 
at 15,000 g, resuspendend in fixative (4%  paraformaldehyde), and then 
sedimented onto poly-L-lysine-coated glass slides. Samples were perme- 
abilized with 0.2% saponin in 100 mM NaCI, 10 mM Tris, pH 7.4, contain- 
ing 1% FCS and 0.5%  BSA as blocking agents. Samples were then in- 
cubated in the presence of anti-TGN38  serum  (1:100  dilution)  with or 
without  1:10t) PY20  antiphosphotyrosine antibody (1:100  dilution), fol- 
lowed by incubation with Cy3TM-eonjugated goat anti-rabbit IgG antibody 
(1:300 dilution) and FITC-conjugated goat anti-mouse IgG antibody (1: 
100 dilution). Slides were examined using a laser scanning confoeal micro- 
scope (model MRC 600; BioRad Labs, Hercules, CA) using identical set- 
tings. Images were processed using Adobe Photoshop  TM  software using 
identical settings except where indicated. 
Results 
Tyrosine Phosphatase  and Kinase Inhibitors  Prevent 
Nascent Secretory  Vesicle Release from the TGN 
To determine if phosphotyrosine metabolism was required 
for nascent secretory vesicle release from the TGN, per- 
meabilized cells were incubated with tyrosine phosphatase 
or tyrosine kinase inhibitors. As observed previously (1, 
11, 37, 62), secretory vesicles containing TGN-derived ra- 
diolabeled Prl,  GH, and proSRIF-derived peptides were 
efficiently released into the 15,000 g supernatant in control 
incubations (Fig. 1, lanes I  and 2). In the presence of the 
tyrosine phosphatase  inhibitors pervanadate or zinc (21, 
47,  61), vesicle release was completely inhibited (Fig.  1, 
lanes  3-6).  The  tyrosine  phosphatase  inhibitor  sodium 
orthovanadate also prevented budding of nascent secre- 
tory vesicles (data not shown). Consistent with earlier ob- 
servations (42), inhibitors of serine/threonine phosphatases 
(up to 5 IxM okadaic acid or 5 mM sodium fluoride) had 
no effect on vesicle budding efficiency (data not shown). 
Based on the preceding data, we anticipated that inhibi- 
tion of tyrosine phosphorylation might stimulate  vesicle 
release. However TA25, a  tyrosine kinase  inhibitor that 
competes with the tyrosine substrate (20, 34), completely 
inhibited release of nascent secretory vesicles (Fig. 1, lanes 
7 and 8). Lav A  and genestein, tyrosine kinase inhibitors 
that compete with ATP (34), also prevented vesicle bud- 
ding,  although somewhat less effectively (Fig.  1, lanes 9 
and 10, and data not shown), most likely because vesicle 
budding reactions contained 1 mM ATP. In contrast, vesicle 
budding was not inhibited by up to 150 nM calphostin C 
(data not shown), a specific inhibitor of protein kinase C. 
Staurosporin, a less selective protein kinase inhibitor, also 
had no significant effect on vesicle release (up to 2.5 txM, 
data not shown), a result consistent with previous observa- 
tions (42). These data suggested that both phosphorylation 
and dephosphorylation of tyrosine residues, but not serine 
or threonine residues, were required for release of nascent 
secretory vesicles from the  TGN.  In  contrast  to  vesicle 
budding, proSRIF processing, which was ~30%  efficient 
in  control  incubations,  was  unaffected  by  inhibitors  of 
phosphotyrosine metabolism (Fig.  1, bottom panel, lanes 
1-10). 
The dose response of secretory vesicle release to the ty- 
rosine phosphatase inhibitor pervanadate (ECs0 ~10 IxM; 
Fig. 2, I1) was similar to that observed for inhibition of 
tyrosine  dephosphorylation in  several  systems  (18,  25, 
47, 49). To ensure that vesicle budding was not inhibited 
by the H20 2 used to generate the pervanadate ion, mock 
incubations  containing  equivalent  amounts  of  catalase- 
treated H~O2 were performed. As expected, there was no 
Figure 1.  Tyrosine phosphatase and kinase inhibitors prevent na- 
scent secretory vesicle release but not proSRIF processing in per- 
meabilized ceils. Pulse-chased permeabilized cells (Materials and 
Methods) were preincubated for 10 min at 4°C without inhibitors 
(lanes I and 2) or with 50 ~M pervanadate (lanes 3 and 4), 25 ixM 
zinc chloride (lanes 5 and 6), 100 p.M TA25 (lanes 7 and 8), or 
100 IxM Lava (lanes 9 and 10), followed by further incubation for 
2 h at 37°C with ATP and GTP. Samples were subsequently sepa- 
rated into pellet (P, lanes 1, 3, 5, 7, and 9) and nascent vesicle- 
containing supernatant (S, lanes 2, 4, 6, 8, and 10) fractions by 
centrifugation at 15,000  g for 10 s and sequential immunoprecipi- 
tations  performed with  rabbit  antisera  to Prl,  GH, and SR1F- 
propeptide. The immunoreactive peptides were resolved by SDS- 
PAGE  and  detected by fluorography,  pS,  proSRIF;  p,  SRIF 
propeptide. 
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Figure 2.  Dose response of nascent secretory vesicle  release to 
tyrosine phosphatase inhibitors.  Permeabilized cells were prein- 
cubated for 10 rain at 4°C with the indicated concentrations of 
catalase-treated pervanadate (1), H202 alone (I-/) (Materials and 
Methods), or zinc chloride (O) followed by further incubation for 
2 h at 37°C with ATP and GTP. Nascent secretory vesicle forma- 
tion was determined by immunoprecipitation using anti-GH se- 
rum followed by densitometric quantitation of the fluorograms. 
The  values  represent  averages from two  similar  experiments. 
Comparable results were obtained using anti-Prl and anti-SRIF 
propeptide serum. 
inhibitory effect (Fig 2, [~). Sodium orthovanadate,  a less 
potent  tyrosine  phosphatase  inhibitor  (18,  53,  59),  pre- 
vented secretory vesicle release at significantly higher con- 
centrations  (ECs0  ~250  p~M; data  not  shown).  Tyrosine 
phosphatases  exhibit differential  sensitivity to zinc, mak- 
ing it a useful diagnostic reagent (61). Zinc was a  slightly 
more  effective  inhibitor  of nascent  vesicle  release  than 
pervanadate  (ECs0 ~2 I~M; Fig. 2, O). The dose response 
of vesicle budding to the  tyrosine kinase  inhibitor TA25 
(ECs0 ~10 p,M; Fig. 3 A, II) was similar to that observed 
for inhibition of EGF receptor and p210  scrabl kinase activ- 
ity  (34).  In contrast,  equivalent  amounts  of the  inactive 
structural  analogue  tyrphostin  A1  (TA1)(20)  had  no in- 
hibitory effect (Fig. 3 A, [3). 
Inhibition of Nascent Secretory Vesicle Release by 
TA25 Is Antagonized by the NH2 Terminus of  ARF1 
Recent studies from our laboratory have implicated ARF1 
and in particular, its amino-terminal peptide (residues 2-17), 
in  stimulating  the  release  of nascent  secretory  vesicles 
from the TGN (11). As observed previously, secretory ves- 
icle release in the absence of TA25 was stimulated approx- 
imately twofold by 25 }xM ARF1 peptide (Fig. 3 B). To de- 
termine  if ARF1  and  tyrosine  phosphorylation  regulate 
vesicle  budding  through  a  common pathway,  permeabi- 
lized  ceils  were  incubated  in  the  presence  of both  the 
ARF1  peptide  and  TA25  simultaneously.  We  reasoned 
that if a shared pathway were involved, the dose response 
to TA25 might be  altered  by the presence  of the ARF1 
peptide.  If,  however,  the  two  agents  influenced  vesicle 
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Figure 3.  Dose response of nascent secretory vesicle  release to 
tyrosine kinase inhibitors.  (A) Tyrphostin A25 and its  inactive 
structural analogue tyrphostin A1. Permeabilized cells were pre- 
incubated for 10 min at 4°C with the indicated concentrations of 
TA25 (11) or TA1 (D) followed by further incubation for 2 h at 
37°C with ATP and GTP. (B) The ARF1 NH2-terminal peptide 
(residues 2-17) antagonizes inhibition of nascent secretory vesi- 
cle budding by tyrphostin A25. Permeabilized cells were first pre- 
incubated for 10 rain at 4°C with the indicated concentrations of 
TA25 followed by addition of 25 IxM ARF peptide for an addi- 
tional 10 min at 4°C (ll). Alternatively, cells were first preincu- 
bated for 10 min at 4°C with 25 IxM ARF1 peptide followed by 
addition  of the indicated concentrations of TA25 for an addi- 
tional 10 min at 4°C (A). Samples were subsequently incubated 
for 2 h at 37°C with ATP and GTP. Nascent secretory vesicle for- 
mation was determined by immunoprecipitation using anti-Prl se- 
rum.  The  values  represent  averages  from two similar  experi- 
ments.  Comparable  results  were  obtained  using  anti-GH  and 
anti-SRIF propeptide serum. 
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fail to modify the dose response to TA25. Consistent with 
the first hypothesis, the ARF1 peptide antagonized the in- 
hibitory effect of TA25, raising the ECs0 three- to fourfold 
(compare Fig. 3 A, •  with 3 B, •  and A). Most signifi- 
cantly, when permeabilized cells were preincubated with 
the ARF1 peptide before addition of TA25 (Fig. 3 B, A), 
the antagonism was more pronounced than when pretreat- 
ment with TA25 preceded ARF1 (Fig. 3 B, •), reinforcing 
the  idea  that  ARF1  peptide  antagonized inhibition  by 
TA25. 
Tyrosine Phosphatase  and Kinase Inhibitors 
Increase Protein Tyrosine Phosphorylation  While 
Inhibiting Nascent Vesicle Budding 
We reasoned that since the above pharmacological pertur- 
bations  inhibited  nascent  secretory  vesicle  release,  it 
should be possible to identify specific changes in protein 
tyrosine phosphorylation that correlated with inhibition of 
vesicle budding. After incubation of permeabilized cells 
with the tyrosine phosphatase and kinase inhibitors, an- 
tiphosphotyrosine immunoblotting was  performed.  Pro- 
tein tyrosine phosphorylation was minimal when vesicle 
release was prevented by low temperature (Fig. 4 A, lanes 
1 and 2) and in control incubations under budding condi- 
tions (Fig. 4 A, lanes 3 and 4). In contrast, incubation with 
50 p~M pervanadate caused marked tyrosine phosphoryla- 
tion relative to control incubations in both cell pellet and 
15,000 g supernatant fractions (Fig. 4 A, compare lanes 5 
and 6 to lanes 3 and 4). Treatment with 50 ~M zinc, which 
appeared to be more selective than pervanadate, also re- 
sulted in protein tyrosine phosphorylation predominantly 
in the pellet fraction (Fig. 4 A, lane 7). Paradoxically, lim- 
ited protein tyrosine phosphorylation was also observed in 
pellet fractions in the presence of tyrosine kinase inhibi- 
tots (Fig. 4 A, compare lanes lanes 9,11, and 13 with lane 3). 
The most conspicuously enhanced band in samples treated 
with 50 ~M TA25, 100 }xM Lav A, or 200  txM genestein 
was a phosphoprotein of ~130 kD (e.g., Fig. 4 A, compare 
lanes 13 and 3, lower arrowhead), although the tyrosine 
phosphorylation of other polypeptides (e.g., ~175 kD and 
90-110  kD) was also increased. These results raised the 
possibility that inhibitors of tyrosine phosphatases and ki- 
nases prevented nascent secretory vesicle release by per- 
mitting increased tyrosine phosphorylation of one or more 
polypeptides, possibly those of ~175, ~130, and 90-110 kD. 
To further test the correlation between protein tyrosine 
phosphorylation and regulation of vesicle budding, the in- 
hibitor dose response of tyrosine phosphorylation was ex- 
amined. In agreement with the zinc-mediated inhibition of 
vesicle release (Fig. 2, O), enhanced protein tyrosine phos- 
phorylation in pellet  fractions required  low micromolar 
levels of zinc (Fig. 4 B, lanes 5-7). However, in samples in- 
cubated with pervanadate,  tyrosine-phosphorylated pro- 
teins appeared at lower concentrations (Fig. 4 B, lanes 2-4), 
although maximal tyrosine phosphorylation occurred  at 
pervanadate levels close to those needed to inhibit vesicle 
release  (Fig.  2,  I1).  Enhanced tyrosine phosphorylation 
also occurred at low micromolar levels of the tyrosine ki- 
nase inhibitor TA25  (Fig. 4  C, lanes 1-5)  but not TA1 
(data not shown), in agreement with the dose response for 
inhibition of vesicle budding (Fig. 3 A, •). Remarkably, 
pretreatment with the NH2-terminal ARF1 peptide signifi- 
cantly reduced the low level of tyrosine phosphorylation 
observed in control incubations (Fig. 4 C, compare lane 6 
with lane 1)  as well as that induced by TA25  (Fig. 4  C, 
compare lanes 7-10 with lanes 2-5), results consistent with 
the  antagonism  observed  between  ARF1  peptide  and 
TA25 for vesicle budding (Fig. 3 B). Antagonism of TA25- 
induced  phosphorylation  was  particularly  evident  for 
polypeptides of ~175 and ~130 kD (Fig. 4 C, arrowheads) 
and somewhat less for other polypeptides including those 
of 90-110 kD (Fig. 4 C, bracket). 
During our standard 2-h  vesicle budding incubation, 
release of nascent secretory vesicles begins after a 15-20- 
min lag (62). If enhanced protein tyrosine phosphorylation 
was indeed responsible  for inhibition of vesicle release, 
phosphorylation would be expected to occur early in the 
incubation with inhibitors, before vesicle budding. The re- 
suits in Fig. 5 confirmed this prediction. In the presence of 
pervanadate, maximal tyrosine phosphorylation occurred 
within 5 min of incubation at 37°C (Fig. 5 A, lanes 3--6). 
Similar kinetics were observed in the presence of zinc (Fig. 
5 A, lanes 8-11). No appreciable tyrosine phosphorylation 
occurred in the presence  of pervanadate  or zinc before 
shifting the temperature to 37°C during the preincubation 
step (Fig. 5 A, compare lane I  with lanes 2 and 7, respec- 
tively). In the presence of TA25, maximal tyrosine phos- 
phorylation  of  several  polypeptides,  including those  of 
N175, ,-o130, and 90-110 kD also occurred within 5 min at 
37°C  (Fig. 5 B, arrowheads and bracket, lanes 1 and 2). 
Other polypeptides, however, such as those of ~30-40 kD 
(Fig. 5 B), became phosphorylated only after prolonged 
(20--60 min) incubation with TA25 and thus were not cor- 
related with inhibition of vesicle budding. Interestingly, ty- 
rosine  phosphorylation  diminished  at  later  time  points 
(Fig. 5 B, lanes 3-5) and could be completely abolished af- 
ter prolonged (2 h) incubations with high (e.g., 200  IxM) 
concentrations of TA25, a  phenomenon not observed at 
lower  inhibitor  concentrations  (data  not  shown).  Thus, 
TA25 had two kinetically distinguishable effects on pro- 
tein  phosphorylation:  (a)  induction  of  phosphorylation 
early in the reaction, and (b) dephosphorylation later in 
the incubation, after completion of events leading to inhi- 
bition of vesicle budding. 
Tyrosine-phosphorylated  Proteins Colocalize with 
the TGN 
We  predicted that  if phosphotyrosine metabolism were 
regulating secretory vesicle release from the TGN, then 
some tyrosine-phosphorylated proteins would be  associ- 
ated with this organelle. To examine this possibility, sub- 
cellular fractionation was performed after incubation of 
permeabilized cells with pervanadate using an equilibrium 
flotation gradient designed to separate Golgi membranes 
from  total  microsomes  (3,  62).  As  previously  demon- 
strated using intact cells (62),  most of the radiolabeled 
Prl,  GH,  and  proSRIF-derived  peptides  cofractionated 
with the TGN marker protein TGN-38 near the top of the 
gradient (Fig. 6, A and B, fractions 2-4), whereas the bulk 
of the total protein remained in the load zone (Fig. 6 D, A, 
fractions 8-11). This N17-fold enrichment of radiolabeled 
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phosphorylation  after  treat- 
ment  of permeabilized cells 
with  inhibitors  of  tyrosine 
phosphatases or kinases. (A) 
Antiphosphotyrosine  immu- 
noblot.  Permeabilized  cells 
were  preincubated  for  10 
min  at  4°C  without  inhibi- 
tors  (lanes 1-4)  or  with  50 
IxM pervanadate (lanes 5 and 
6),  50  ~M  zinc  chloride 
(lanes 7 and 8), 50 ~M TA25 
(lanes 9 and 10), 100 ~M Lav 
A  (lanes 11  and 12), or 200 
I~M genestein (lanes 13 and 
14) followed by further incu- 
bation  for  30  min  at  370C 
with ATP and GTP (lanes 3- 
14). Samples were then sepa- 
rated into cell pellet (P) and 
nascent  vesicle-containing 
supematant (S) fractions. (B) 
Dose  response  to  tyrosine 
phosphatase  inhibitors.  Per- 
meabilized ceils were  prein- 
cubated  with  or  without 
(lane  1)  the  indicated  con- 
centrations  of  pervanadate 
(lanes 2-4)  or zinc chloride 
(lanes 5-7) followed by incu- 
bation for 2  h  at 37°C.  Cell 
pellet  fractions  are  shown. 
(C) Dose response to the ty- 
rosine kinase inhibitor TA25 
in the presence or absence of 
the ARF1 NH2-terminal pep- 
tide.  Permeabilized  cells 
were preincubated for 10 min 
at 4°C without (lanes 1-5) or 
with  25  ixM  ARF1  peptide 
(lanes 6-10) followed by ad- 
dition of the  indicated con- 
centrations of TA25 and pre- 
incubation for an  additional 
10 min at 4°C. Samples were 
subsequently incubated for 2 
h  at  37°C  with  ATP  and 
GTP. Cell pellet fractions are 
shown.  In  each  experiment, 
the  total  protein  was  re- 
solved by SDS-PAGE, trans- 
ferred to PVDF membranes, 
and  analyzed  by  antiphos- 
photyrosine  immunoblotting 
(Materials  and  Methods). 
Upper arrowhead, ,'~175-kD 
polypeptide;  lower  arrow- 
head, ,'~130-kD  polypeptide; 
bracket, 90-110-kD polypep- 
tides. 
hormones per mg protein in fractions 2-4 relative to the 
load zone  indicated that  the  subcellular distribution was 
maintained  after  in  vitro  incubation  with  pervanadate, 
consistent with the inability of secretory vesicle cargo to 
exit the TGN when vesicle budding was blocked. Most sig- 
nificantly, antiphosphotyrosine immunoblotting of the gra- 
dient fractions revealed that the ~175-, ~130-, and 90-110- 
kD phosphorylated proteins were also enriched (~14-fold 
per mg protein) in fractions 2-4 relative to the load zone 
(Fig. 6 C, arrowheads and bracket). In contrast, other ma- 
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in incubations with inhibitors of tyrosine phosphatases or kinases. 
(A) Kinetics of tyrosine phosphorylation  after treatment with ty- 
rosine phosphatase  inhibitors. Permeabilized cells were preincu- 
bated without (lane 1) or with 50 ~.M pervanadate (lanes 2-6) or 
50 I~M zinc chloride  (lanes  7-11)  followed  by incubation  with 
ATP and GTP for the indicated times at 37~C (lanes 2-11). Cell 
pellet fractions are shown. (B) Kinetics of tyrosine phosphoryla- 
tion after treatment with tyrosine  kinase  inhibitors.  Permeabi- 
lized cells were preincubated with 50 I~M TA25 followed by incu- 
bation for the indicated times at 37°C with ATP and GTP (lanes 
2-5). Cell pellet fractions are shown. Samples were analyzed by 
jor tyrosine-phosphorylated proteins,  e.g.,  30-40-kD  poly- 
peptides, remained near the bottom of the gradient (Fig. 6 
C, fractions 9-13). 
The cell surface is a well-known site of protein tyrosine 
phosphorylation (60). To test the possibility that the high- 
molecular weight tyrosine-phosphorylated proteins in gra- 
dient fractions 2-4 reflected contamination with plasma 
membrane, we also examined the gradient distribution of 
total cell surface protein. Before permeabilization, intact 
cells were exposed to TNBS, which results in the covalent 
attachment  of TNP moieties to  externally exposed pro- 
teins (22 and references within). Total plasma membrane 
proteins could then be monitored on immunoblots using 
anti-DNP  antiserum.  The  anti-DNP  signal  consisted  of 
multiple bands and was very specific (>15-fold increase in 
signal after TNBS labeling, data not shown). When intact 
cells were labeled with TNBS just before cell permeabili- 
zation and incubation with pervanadate, the anti-DNP sig- 
nal remained almost entirely near the bottom of the gradi- 
ent and cofractionated with the bulk of the total protein 
(Fig. 6 D, II, fractions 8-11). This suggested that the ty- 
rosine phosphorylated proteins in fractions 2-4 were not 
derived from en masse plasma membrane contamination. 
It might  be  argued, however, that these  high-molecular 
weight  tyrosine-phosphorylated  proteins  were  derived 
from the temporal pool of membrane protein exposed at 
the  cell  surface  before  the  19°C  chase  and  had  subse- 
quently changed subcellular distribution during the 19°C 
chase. To examine this possibility, intact cells were labeled 
with TNBS before the 19°C chase. After cell permeabiliza- 
tion and incubation with pervanadate, the anti-DNP signal 
again remained almost entirely near the bottom of the gra- 
dient (Fig. 6 D, O, fractions 8-11). These results demon- 
strated that the tyrosine-phosphorylated proteins found to 
cofractionate with TGN membranes in fractions 2-4 were 
not  due  to  bulk  plasma  membrane  contamination  pro- 
duced by the 19°C chase. Selective contamination by indi- 
vidual cell surface proteins that comprise a very small per- 
centage of total cell surface protein, however, cannot be 
excluded. 
To confirm that  tyrosine-phosphorylated polypeptides 
were localized to the TGN, we performed double-label in- 
direct immunofluorescence using the antiphosphotyrosine 
antibody together with anti-TGN38 serum. Although the 
cells had been permeabilized and incubated under a vari- 
ety  of  conditions,  the  TGN38-immunoreactive material 
displayed a perinuclear staining pattern characteristic of the 
TGN and Golgi apparatus (Fig. 7, left,  Fig. 8). Significant 
FITC-staining of cell nuclei was observed in all samples 
(Fig.  7,  middle),  even in  the  absence  of antiphosphoty- 
rosine  antibody  (Fig.  7  A,  middle)  resulting  from non- 
specific binding of FITC-conjugated secondary antibody. 
We predicted that after pervanadate treatment of perme- 
abilized cells, antiphosphotyrosine-specific staining would 
increase in the cytoplasmic region of the cells, including 
the  TGN.  In  agreement  with  our  immunoblotting  data 
(Fig.  6  C),  pervanadate treatment  enhanced phosphoty- 
antiphosphotyrosine immunoblotting. Upper arrowhead, ~175-kD 
polypeptide;  lower arrowhead,  ~130-kD  polypeptide;  bracket, 
90-110-kD polypeptides. 
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Zinc or TA25 treatment resulted in less cytoplasmic stain- 
ing, but with preserved TGN colocalization (Fig. 7, E  and 
F, arrows and right). No FITC staining was observed in the 
cytoplasmic region after incubation in the absence of in- 
hibitors at either 4°C (Fig. 7 B, middle) or under budding- 
permissive conditions at 37°C (Fig. 7 C, middle), indicating 
that in inhibitor-treated samples, cytoplasmic staining was 
phosphotyrosine specific. Moreover, pretreatment  of the 
phosphotyrosine  antibody with  either phosphotyrosine  or 
phenyl phosphate abolished this staining (data not shown). 
This data  provided further  evidence that inhibitor treat- 
ment enhanced protein tyrosine phosphorylation at the TGN 
while inhibiting secretory vesicle release. 
Membrane Association of 
Tyrosine-phosphorylated Proteins 
Incubation  of permeabilized  cells  with  pervanadate  re- 
sulted  in  appearance  of significant  amounts  of tyrosine- 
phosphorylated proteins in the low-speed (15,000 g) super- 
natant as well as in the pellet fraction (Fig. 4 A, lanes 6 and 5, 
respectively), an effect not observed with the other inhibi- 
tors.  Tyrosine-phosphorylated  proteins  appeared  in  the 
low-speed supernatant primarily between 5 and 20 min of 
incubation with pervanadate at 37°C (data not shown). Be- 
cause these vesicle-release assays were performed under 
conditions  in  which  exogenous  cytosol was  not  required 
(62),  the  phosphorylated  proteins  appearing in  the  low- 
speed supernatant  must have been membrane-associated 
before incubation at 37°C.  It was possible that these pro- 
teins were loosely associated with membranes and solubi- 
lized during incubation at 37°C.  Alternatively, these pro- 
teins could have been components of nascent vesicles that 
did not contain radiolabeled hormones. It is unlikely that 
this  phenomenon  represented  nonspecific fragmentation 
of the TGN/Golgi because pervanadate treatment did not 
result in  appearance of TGN lumenal contents  (radiola- 
beled  hormones)  in  the  low-speed  supernatant  fraction 
(Fig.l, lane 4). To further exclude this possibility, we com- 
pared the morphological localization of the marker pro- 
tein TGN-38 in permeabilized cells before and after per- 
vanadate  treatment  (Fig.  8).  The  overall distribution  of 
TGN-38 was unchanged (compare Fig. 8, A and B), suggest- 
Figure 6.  High-molecular weight  tyrosine-phosphorylated pro- 
teins cofractionate with TGN markers. Permeabilized cells were 
preincubated with  100 txM pervanadate followed  by incubation 
for 30 min at 37°C with ATP and GTP. The permeabilized cells 
were homogenized and the homogenate fractionated on an equi- 
librium  flotation gradient designed  to separate the TGN/Golgi 
apparatus from total microsomes (Materials and Methods).  (A) 
An aliquot  from each fraction was sequentially  immunoprecip- 
ited with antisera to Prl, GH, and SRIF-propeptide (pS) followed 
by SDS-PAGE and fluorography.  (B) An aliquot of each fraction 
was transferred to PVDF membrane and immunoblotted with 
anti-TGN38 antiserum. Mature, polysialylated TGN38 appears as 
a smeared doublet at ~85 kD (30). (C) An aliquot  of each frac- 
tion was  transferred to  PVDF membrane and  immunoblotted 
with antiphosphotyrosine antibody.  Upper arrowhead, ~175-kD 
polypeptide; lower arrowhead, ~130-kD  polypeptide; bracket, 
90-110-kD polypeptides.  (D) Distribution of total protein (A). In 
separate  experiments,  intact  cells  were  surface  labeled  with 
TNBS either before(Q) or after (11) incubation  at 19°C (Materi- 
als and Methods),  permeabilized,  and preincubated with 100 ixM 
pervanadate followed by incubation  for 30 min at 37°C with ATP 
and GTP. Cell homogenates were fractionated and aliquots ana- 
lyzed by anti-DNP immunoblotting and densitometry. 
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tion  of  tyrosine-phosphory- 
lated proteins with the TGN 
in permeabilized cells treated 
with  inhibitors.  Permeabi- 
lized cells were preincubated 
at 4°C for 10 min without (A- 
C)  or with  50  I~M pervana- 
date  (D),  50  I~M zinc chlo- 
ride (E), or 50 o,M TA25 (F), 
followed  by  incubation  at 
37°C  for  10  min  with  ATP 
and  GTP (C-F).  Cells  were 
subsequently fixed and  ana- 
lyzed by double-staining  in- 
direct  immunofluorescence 
confocal  microscopy  (Mate- 
rials  and  Methods)  using 
anti-TGN38  primary  antise- 
rum  with  Cy3TM-conjugated 
secondary antibody (left) and 
antiphosphotyrosine  pri- 
mary  antibody  with  FITC- 
conjugated  secondary  anti- 
body (middle). To determine 
background  FITC  staining, 
antiphosphotyrosine  primary 
antibody  was  omitted  from 
one sample  (A). To demon- 
strate  overlap of phosphoty- 
rosine and TGN38, the FITC 
(green) and Cy3  TM  (red) im- 
ages  were  digitally  merged 
(right). Arrows (left and mid- 
dle  columns)  also  identify 
phosphotyrosine  colocaliza- 
tion with TGN38. All images 
were  captured  identically. 
The  cytoplasmic FITC fluo- 
rescence  of  pervanadate- 
treated  cells  (D, middle and 
right) was higher than the other 
samples, and therefore a lower 
gain setting was used during 
image processing (*)  to pre- 
serve contrast. Bar, 10 IxM. 
ing  that  the  integrity  of the  Golgi  apparatus/TGN  was 
maintained after incubation in the presence of pervanadate. 
To determine  if the high-molecular weight phosphory- 
lated proteins present in the 15,000 g supernatant fraction 
were  membrane-associated  or soluble,  this  material  was 
subjected  to  several  extraction  conditions  followed  by 
high-speed centrifugation (150,000 g). Antiphosphotyrosine 
immunoblot  analysis revealed that the tyrosine-phospho- 
rylated proteins could be sedimented at high-speed (Fig. 9, 
lanes 1  and 2), indicating that these proteins were indeed 
membrane associated.  When samples were first extracted 
with high salt (1 M NaCI) or high pH (100 mM Na-carbon- 
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after pervanadate  treatment.  Permeabilized ceils were preincu- 
bated at 4°C for 10 min without (A) or with (B) 50 p,M pervana- 
date followed by incubation at 37°C for 10 min with ATP and 
GTP (B). Cells were analyzed using identical settings by both 
Normarski optics and indirect immunofluoresence eonfocal mi- 
croscopy using anti-TGN-38  antiserum  and Cy3aU-conjugated 
secondary antibody (red). Identical results were obtained with 
permeabilized cells incubated in the absence of inhibitors, the 
presence of 50 p~M zinc chloride, or 50 p~M TA25 (not shown). 
ate,  pH  11.5),  the  ~175-,  ~130-,  and  90-110-kD  phos- 
phoproteins  remained in  the  high-speed pellet fractions 
whereas the ~30--40-kD phosphoproteins redistributed to 
the supernatant (Fig. 9, lanes 3-6). In contrast, upon treat- 
ment  with  the  detergent  TX-100,  the  high-molecular 
weight phosphopolypeptides redistributed to the 150,000 g 
supernatant (Fig. 9, lanes 7 and 8). These results suggested 
that the ~175-, ~130-, and 90-110-kD  tyrosine phospho- 
rylated proteins  were  tightly membrane  associated  and 
possibly integral membrane proteins. A characteristic fea- 
ture of many integral membrane proteins is their partition- 
ing into the detergent phase upon TX-114  extraction at 
37°C  (7).  Surprisingly, the  high-molecular weight phos- 
phoproteins partitioned into the aqueous phase after TX- 
114 treatment (Fig. 9, lanes 9-11). Similar results were ob- 
tained in an identical analysis of the tyrosine-phosphory- 
lated proteins from TGN-enriched gradient fractions (data 
not shown). 
Discussion 
Nascent Secretory  Vesicle Release Requires Both 
Tyrosine Phosphatase  and Kinase Activities 
Our results demonstrated that inhibitors of tyrosine phos- 
phatases and kinases prevented release of nascent secre- 
tory vesicles from the TGN of permeabilized neuroendo- 
trine cells. Several observations demonstrated that these 
agents were specific: (a) various structurally distinct inhib- 
itors of phosphotyrosine metabolism inhibited secretory 
vesicle budding (Fig. 1), whereas the tyrosine kinase inhib- 
itor analogue TA1 (Fig. 3 A), as well as inhibitors of phos- 
phoserine/threonine metabolism (data not shown), had no 
effect; (b) effective concentrations of each inhibitor (Figs. 
2 and 3 A) induced changes in the tyrosine phosphoryla- 
tion status of proteins (Fig. 4) early in the incubations (Fig. 5) 
and were similar to concentrations reported for inhibition 
of tyrosine phosphatases and kinases in other systems (18, 
25, 34, 47, 49); (c) pretreatment with ARF1 peptide antag- 
onized the inhibitory and phosphorylation-enhancing ef- 
fects of the tyrosine kinase inhibitor TA25 (Figs. 3 B and 
4  C,  respectively); (d)  tyrosine-phosphorylated proteins 
immunolocalized with the TGN (Fig. 7); (e) phosphopro- 
teins implicated in vesicle budding were tightly membrane 
associated (Fig. 9) and highly enriched in Golgi fractions 
containing TGN marker proteins (Fig. 6); and (f) both the 
gross morphological appearance of the TGN (Fig. 8) and 
processing of proSRIF were unaffected (Fig.  1).  Protein 
tyrosine dephosphorylation has been shown to be involved 
in  regulated  exocytosis  (for  example  see  27).  To  our 
knowledge however,  this  is  the  first  report  implicating 
phosphotyrosine metabolism in secretory vesicle  forma- 
tion. 
Treatment with tyrosine phosphatase inhibitors led to 
rapid protein tyrosine phosphorylation (Fig. 5 A) and re- 
vealed that tyrosine kinases were active under these condi- 
tions. The somewhat surprising observation that treatment 
with tyrosine kinase inhibitors also led to rapid protein ty- 
rosine phosphorylation demonstrated that at least one ty- 
rosine kinase was resistant to these inhibitors (see below). 
Measurements of the dose response (Fig. 4, B and C) and 
kinetics (Fig. 5, A and B) of phosphorylation provided fur- 
ther correlation between tyrosine phosporytation and reg- 
ulation of vesicle budding. A potential complication of the 
immunoblotting experiments is that proteins phosphory- 
lated on tyrosine often contain multiple, functionally dis- 
tinct phosphorylation sites (60).  Consequently, treatment 
with a broad-spectrum tyrosine phosphatase inhibitor such 
as  pervanadate  may  enhance  phosphorylation  of  addi- 
tional sites as welt as those relevant to  vesicle  release. 
Consistent with this idea, maximal tyrosine phosphoryla- 
tion achieved with pervanadate exceeded that of zinc, a 
narrow-spectrum tyrosine phosphatase inhibitor (61). Phos- 
phorylation of functionally irrelevant  sites  may explain 
why significant phosphorylation was observed at pervana- 
date concentrations insufficient to prevent vesicle release. 
Indeed, significant amounts of vesicle membrane-associ- 
ated  phosphoprotein  were  released  after  incubation  of 
permeabilized  cells  with pervanadate;  this  was  not  ob- 
served  with  other  inhibitors  (Fig.  4  A).  These  vesicles 
could have been nascent secretory vesicles in which the 
hormone cargo was not packaged. Thus, the possibility re- 
mains that pervanadate  or any of the  other phosphoty- 
rosine metabolism inhibitors interfered with filling of vesi- 
cles  (i.e., hormone sorting) rather than budding per  se. 
Alternatively, these vesicles could be nonsecretory TGN- 
derived vesicles, or derived from membranes other than 
the TGN. 
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Tyrosine-phosphorylated  Proteins Are Putative 
Regulators  of Secretory  Vesicle Formation 
The  observation that the  ~175-,  ~130-,  and 90-110-kD 
phosphoproteins were  enriched in TGN-containing sub- 
cellular fractions implicated these polypeptides in secre- 
tory vesicle  budding. Tyrosine phosphorylation of these 
polypeptides correlated with inhibition of vesicle budding 
with respect to inhibitor close response and kinetics (Fig. 4). 
After treatment with various tyrosine kinase inhibitors, ty- 
rosine  phosphorylation was  particularly evident  for  the 
~130-kD  polypeptide and less so for the ,'-d75-  and 90- 
ll0-kD polypeptides. Furthermore, ARF1 peptide antag- 
onism of tyrosine phosphorylation was most evident for 
the  ~130-  and ,'-d75-kD  polypeptides (Fig. 4  C). These 
data provide correlative evidence that tyrosine phosphory- 
lation of one or more of these polypeptides inhibit vesicle 
budding.  However,  direct proof that  the  ~175-,  ~130-, 
and 90--ll0-kD  phosphoproteins regulate vesicle forma- 
tion will require their purification and reconstitution in a 
highly purified vesicle budding system. 
The  tyrosine-phosphorylated proteins  that  cofraction- 
ated with the TGN were tightly membrane associated and 
required detergent treatment for removal (Fig. 9). It is un- 
likely, therefore, that these proteins were adventitiously 
associated  with  Golgi  membranes.  A  characteristic  of 
many integral membrane proteins is their detergent-phase 
partitioning  in  the  detergent  TX-114  upon  warming  to 
37°C  (7).  Surprisingly, the  high-molecular weight phos- 
phoproteins partitioned with the aqueous phase after TX- 
114 phase separation, suggesting that these proteins were 
either very tightly membrane-associated peripheral  pro- 
teins or integral membrane proteins with substantial hy- 
drophilicity that precluded efficient partitioning into the 
TX-114 detergent phase (48). 
Antagonism between Tyrphostin A25 and ARF1 Peptide 
Our results also suggested that both TA25 and the NH  z- 
terminal ARF1 peptide affected the same pathway leading 
to secretory vesicle release. Pretreatment with the ARF1 
peptide not only shifted the TA25 dose response curve to 
the right but also reduced basal and TA25-induced tyro- 
sine phosphorylation. It is difficult to integrate these re- 
sults into a model in which ARF1 serves simply as a struc- 
tural constituent of vesicle coats. However, recent studies 
revealing that ARF1  activates phospholipase  D  (PLD) 
(10, 12, 31, 32) and interacts directly with heterotrimeric G 
proteins (5, 13, 50) suggest that ARF1 may regulate intra- 
cellular membrane trafficking events through a novel sig- 
nal transduction pathway. In fact, recent evidence from 
our  laboratory  suggests  that  ARF1  stimulates  nascent 
secretory vesicle release through activation of PLD (Chen 
et al., manuscript submitted for publication). Interestingly, 
tyrosine phosphorylation has also been implicated in the 
regulation of PLD activity (9, 28, 29). 
A Model For Regulation of Secretory  Vesicle Budding 
by Phosphotyrosine  Metabolism 
It might be argued that the observation that vesicle release 
was prevented by inhibitors of both tyrosine phosphatases 
Figure 9.  High-molecular  weight tyrosine-phosphorylated  pro- 
teins are tightly membrane associated. Approximately 107 perme- 
abilized cells were treated with 100 p,M pervanadate for 30 min 
and centrifuged at 15,000 g for 10 s. Supernatant aliquots were in- 
cubated for 30 rain at 4°C under the following conditions: no ex- 
traction  (lanes 1 and 2),  1 M NaC1 (lanes 3 and 4), 100 mM 
Na2CO  3, pH 11.5 (lanes 5 and 6), 1% Triton X-100 (lanes 7 and 
8), and 1% Triton X-114 (lanes 9-11). Samples were then centri- 
fuged at 150,000 g for 20 min to generate pellet (P) and high- 
speed  supernatant  (S)  fractions.  The  Triton X-114 detergent 
phase (lane 10) was separated from the aqueous phase (lane 11) 
of the high-speed supernatant by incubating 3 rain at 37°C and 
then centrifuging at room temperature for 3 min at 800 g through 
a 6%  sucrose cushion (7). All fractions were analyzed by an- 
tiphosphotyrosine immunoblotting (Materials and Methods). Up- 
per arrowhead, ,~175-kD polypeptide; lower arrowhead, ~130-kD 
polypeptide; bracket, 90--ll0-kD polypeptides. 
and  kinases  is  contradictory. However,  cooperation be- 
tween  tyrosine  phosphatases  and  kinases  is  well  docu- 
mented (for reviews see 17, 57, 58, 60). For example, mem- 
bers of the Src tyrosine kinase family can be activated by 
tyrosine dephosphorylation of their negative regulatory 
sites  by  the  receptor  tyrosine  phosphatases  CD45  and 
PTP~t  (17).  CD45  phosphatase activity is required for T 
lymphocyte antigen receptor-induced tyrosine phosphory- 
lation,  phosphatidylinositol turnover,  and  Ca  2÷  release 
from intracellular stores (58).  In addition, the widely ex- 
pressed  nonreceptor  tyrosine phosphatase  SH-PTP2  (or 
SYP) associates via its SH2 domains with several activated 
receptor tyrosine kinases, leading to stimulation of phos- 
phatase activity (57, 58). SH-PTP2 does not dephosphory- 
late the activated receptors, but is instead a positive signal- 
ing transducer; SH-PTP2 phosphatase activity is required 
for receptor tyrosine kinase-mediated responses, possibly 
via Src-family kinases (17, 57, 58). Tyrosine phosphatases 
that serve as negative transducers of signaling can also co- 
operate with specific tyrosine phosphorylation events. In 
hematopoietic cells for instance, SH-PTP1  (HCP) termi- 
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larly activated  upon  binding  to  tyrosine-phosphorylated 
molecules via its SH2 domain. Likewise, while our results 
suggested that secretory vesicle release required coopera- 
tion between a tyrosine phosphatase and kinase, they do 
not  preclude  the  possibility that  additional  antagonistic 
phosphatase-kinase relationships also exist. 
To explain our observations, we propose a model (Fig. 
10) in which the net level of tyrosine phosphate in the tar- 
get substrate (e.g., the ~130-kD polypeptide, p130) is de- 
termined by the balance of tyrosine phosphatase (PTPase) 
and inhibitor-resistant kinase (PTKR) activities. Direct in- 
hibition of PTPase activity by pervanadate or zinc disrupts 
this balance, resulting in enhanced p130 phosphorylation 
and inhibition of secretory vesicle formation. Treatment 
with tyrosine kinase inhibitors (e.g., TA25) has a similar 
consequence early in the budding reaction by indirectly in- 
hibiting PTPase activity, while having a slower or lesser ef- 
fect on the activity of PTKR. It should be emphasized that 
this model is a working hypothesis that explains our obser- 
vations most simply and could apply equally to any or all 
the phosphotyrosine polypeptides we have identified; vali- 
dation  of this  model  will  require  reconstitution  experi- 
ments using purified components. 
At present we can only speculate how phosphotyrosine 
metabolism might participate in the regulation of secre- 
tory vesicle formation. One possibility is that unidentified 
receptor tyrosine kinases and/or phosphatases on the TGN 
membrane transduce signals from the TGN lumen to the 
cytoplasm in response to interaction with cargo proteins 
(hormones). At the cell surface, receptor tyrosine kinases 
and  phosphatases  bind  ligand  in  a  space  topologically 
equivalent to the TGN lumen. Receptor activation leads 
to recruitment of several effector molecules, which in turn 
PTKR 
l 
Budding ("  ,~  ~  ~  ~?]'~,  :~- No Budding 
pVan, Zn2÷~'--!  l 
PTKs 
PTPaseac.ve. 
PTP  s  8  elnactlve 
Figure 10.  A working model for regulation  of secretory vesicle 
budding by phosphotyrosine  metabolism. It is proposed that de- 
phosphorylation  of a phosphoprotein (possibly p130) is required 
for nascent secretory vesicle formation from the TGN. The net 
level of tyrosine phosphate in p130 is determined by the balance 
of tyrosine phosphatase  (FrPaseacuv~) and inhibitor-resistant  ki- 
nase  (PTKR) activities. Direct inhibition  of the tyrosine  phos- 
phatase with pervanadate (pVan) or Zn  2+ leads to enhanced p130 
phosphorylation  and  inhibition  of vesicle budding.  Treatment 
with tyrosine kinase inhibitors such as TA25 has a similar conse- 
quence by preventing PTPase activation via a phosphorylation 
event mediated by an inhibitor-sensitive tyrosine kinase (PTKs). 
modulate downstream signaling pathways similar to those 
implicated in secretory vesicle release from the TGN (60). 
Interestingly, internalization and sorting of activated re- 
ceptor tyrosine kinases from the plasma membrane to ly- 
sosomes requires kinase activity (33; for review see 2). The 
formation of coated pits on the cell surface appears to be 
regulated by the activated receptors indirectly, via recep- 
tor-mediated  signaling  pathways  (52).  It  is  conceivable 
that in our system, a tyrosine phosphatase links a stimu- 
lated TGN sorting receptor to the activation of ARF and 
hence to the mobilization of vesicle budding machinery. 
Further dissection of this pathway using our permeabilized 
cell system will enable us to address these hypotheses di- 
rectly. 
We dedicate this paper to Giinter Blobel on the occasion of his sixtieth 
birthday. 
We thank Drs. Wai Lam W. Ling, Yeguang Chen, Duncan Wilson, and 
Tamar Michaeli  for helpful suggestions and discussions and Michael Cam- 
mer for help with the confocal microscopy experiments. 
This work was supported by National Institutes of Health (NIH) grant 
DK21860 and in part by a grant from the Juvenile Diabetes Foundation to 
D. Shields.  C.D. Austin was supported by a  Life  and Health Insurance 
Medical  Research Fund M.D.-Ph.D. Scholarship. Core support was pro- 
vided by an NIH Cancer Center grant P30CA13330. 
Received for publication 13 June 1996 and in revised form 9 September 
1996. 
References 
1. Austin, C.D., and D. Shields. 1996. Prosomatostatin  processing in perme- 
abilized cells. Calcium is required for prohormone processing but not for- 
mation of nascent secretory vesicles. J. Biol. Chem. 271:1194-1199. 
2. Baass, P.C., G.M. Di Guglielmo, F. Authier,  B.I. Posner, and J.J.M. Ber- 
geron. 1995. Compartmentalized  signal transduction by receptor tyrosine 
kinases. Trends Cell Biol. 5:465-470. 
3. Beckers, C.J.M., D.S. Keller, and W.E. Balch. 1987. Semi-intact ceils per- 
meable  to macromolecules:  use in reeonstitution  of protein transport 
from the endoplasmic reticulum to the gnlgi complex. Cell. 50:523-534. 
4. Bennett,  M.K., and R.H. Scheller. 1993. The molecular machinery for se- 
cretion is conserved from yeast to neurons.  Proc. Natl. Acad. Sci.  USA. 
90:255%2563. 
5. Boman, A.L., and R.A. Kahn. 1995. Affproteins: the membrane traffic po- 
lice. Trends Biochem. Sci. 20:147-150. 
6. Bomsel, M., and  K. Mostov.  1992, Role  of heterotrimerie  G proteins  in 
membrane traffic. Mol. Biol. Cell. 3:1317-1328. 
7. Bordier, C. 1981. Phase separation  of intergral membrane proteins in Tri- 
ton X-114 solution. J. Biol. Chem. 256:1604-1607. 
8. Bradford, M.M. 1976. A rapid and sensitive method for the quantitation  of 
microgram  quantities  of protein  utilizing the  principle  of protein-dye 
binding. Anal. Biochem. 72:248-254. 
9. Briscoe, C.P., A. Martin, M. Cross, and MJ.O. Wakelam. 1995. The roles 
of multiple pathways in regulating bombesin-stimulated phospholipase D 
activity in Swiss 3T3 fibroblasts. Biochem. J. 306:115-122. 
10. Brown, H.A.,  S. Gutowski, C.R. Moomaw, C. Slaughter, and P.C. Stern- 
weis. 1993. ADP-ribosylation  factor, a small GTP-dependent  regulatory 
protein, stimulates phospholipase D activity. Cell. 75:1137-1144. 
11. Chen, Y.-G., and  D. Shields. 1996. ADP-ribosylation  factor-1 stimulates 
formation of nascent secretory vesicles from the trans-Golgi network of 
endocrine cells. J. Biol. Chem. 271:5297-5300. 
12. Cockcroft, S., G.M.H. Thomas, A. Fensome, B. Geny, E. Cunningham, I. 
Gout, I. Hiles, N.F. Totty, O. Truong, and J.J. Hsuan. 1994. Phospholi- 
pase D: a downstream effector of ARF in granulocytes. Science (Wash. 
DC). 263:523-526. 
13. Colombo, M.I., J. Inglese, C. D'Souza-Schorey, W. Beron, and P.D. Stahl. 
1995. Heterotrimeric  G proteins  interact  with the small GTPase  ARF. 
Possibilities for the  regulation  of vesicular traffic. J.  BioL  Chem.  270: 
24564-24571. 
14. De Camilli, P., S.D. Emr, P.S. McPherson, and P. Novick. 1996. Phosphoi- 
nositides  as regulators  in membrane traffic. Science (Wash.  DC).  271: 
1533-1539. 
15. Donaldson, J.G., and R.D. Klausner. 1994. ARF: a key regulatory switch in 
membrane traffic and organelle structure.  Curr.  Opin.  Cell Biol. 6:527- 
532. 
16. Elgort,  A., and D. Shields. 1994. Prosomatostatin  processing in pituitary 
GH3 cells. Identification  and secretion of the intact propeptide. J. Biol. 
The Journal of Cell Biology, Volume 135, 1996  1482 Chem. 269:30668--30675. 
17. Erpel, T, and S.A. Courtneidge.  1996. Src family protein  tyrosine kinases 
and cellular signal transduction pathways. Curr. Opin. Cell Biol. 7:176--182. 
18. Fantus, G., S. Kadota, G. Deragon,  B. Foster, and B.I. Posner. 1989. Per- 
vanadate  [peroxide(s)  of vanadate]  mimics insulin action  in rat adipo- 
cytes via activation of the insulin receptor tyrosine kinase. Biochemistry. 
28:8864---8871. 
19. Ferro-Novick, S., and R. Jahn. 1994. Vesicle fusion from yeast to man. Na- 
ture (Lond.). 370:191-193. 
20.  Gazit, A., P. Yaish, C. Gilon, and A. Levitzki. 1989. Tyrphostins I: synthesis 
and  biological  activity  of protein  tyrosine  kinase  inhibitors.  J.  Med. 
Chem. 32:2344-2352. 
21. Gordon, J.A.  1991. Use of vanadate  as  protein-phosphotyrosine  phos- 
phatase inhibitor. Methods Enzymol. 201:477-482. 
22. Green, R., and D. Shields. 1984. Somatostatin  discriminates between  the 
intracellular  pathways of secretory and membrane proteins. J. Cell Biol. 
99:97-104. 
23. Hay, J.C., and T.F.J. Martin. 1993. Phosphatidylinositol transfer protein re- 
quired  for ATP-dependent  priming of Ca2+-activated secretion. Nature 
(Lond.). 366:572-575. 
24. Hay,  J.C., P.L. Fisette,  G.H.  Jenkins,  K.  Fukami,  T.  Takenawa,  R.A. 
Anderson, and T.F.J. Martin. 1995. ATP-dependent  inositide phosphory- 
lation required for Ca2+-activated secretion. Nature (Lond.). 374:173-177. 
25. Heffetz, D., I. Bushkin, R. Dror, and Y. Zick. 1990. The insulinomimetic 
agents H202 and vanadate stimulate protein tyrosine phosphorylation  in 
intact cells. J. Biol. Chem. 265:2896-2902. 
26. Huber, L.A., S. Pimplikar, R.G. Parton, H. Virta, M. Zerial, and K. Simons. 
1993. Rab8,  a small GTPase  involved in vesicular traffic between  the 
TGN and the basolateral plasma membrane. Z Cell Biol. 123:35-45. 
27. Jena, B.P., P.J. Padfield, T.S. lngebritsen, and J.D. Jamieson. 1991. Protein 
tyrosine phosphatase  stimulates Ca2+-dependent amylase secretion from 
pancreatic acini. J. Biol. Chem. 266:17744-17746. 
28. Jiang, H., Z. Lu, J.-Q. Luo, A. Wolfman, and D.A. Foster. 1995. Ras medi- 
ates the activation of phospholipase D by v-Src. J. Biol. Chem. 270:6006- 
6009. 
29. Jiang, H., J.-Q. Luo, T. Urano, P. Frankel,  Z. Lu, D.A. Foster,  and L.A. 
Feig. 1995. Involvement  of Ral GTPase in v-Src-induced phospholipase 
D activation. Nature (Lond.). 378:409-412. 
30. Jones, S.M., J.R. Crosby, J. Salamero, and K.E. Howell. 1993. A cytosolic 
complex of p62 and rab6 associates with TGN38/41 and is involved in 
budding of exocytic vesicles from the trans-Gol~ network. J.  Cell Biol. 
122:775-788. 
31. Ktistakis, N.T., H.A. Brown, P.C. Sternweis, and M.G. Roth.  1995. Phos- 
pholipase D is present on Golgi-enriched membranes and its activation 
by ADP ribosylation factor is sensitive to brefeldin A. Proc. Natl. Acad. 
Sci.  USA. 92:4952--4956. 
32. Ktistakis, N.T., H.A. Brown, M.G. Waters, P.C. Sternweis, and M.G. Roth. 
1996. Evidence that phospholipase D mediates ADP ribosylation factor- 
dependent formation of Golgi coated vesicles. J. Cell Biol. 134:295-306. 
33. Lamaze, C., and S.L. Schmid. 1995. Recruitment  of epidermal growth fac- 
tor receptors  into coated pits requires  their activated tyrosine kinase. J. 
Cell Biol. 129:47-54. 
34. Levitzki, A., and A. Gazit. 1995. Tyrosine kinase inhibition: an approach to 
drug development. Science (Wash. DC). 267:1782-1788. 
35.  Leyte, A., F.A. Barr, R.H. Kehlenbach, and W.B. Huttner.  1992. Multiple 
trimeric G-proteins on the trans-Golgi network exert stimulatory and in- 
hibitory effects on secretory vesicle formation. EMBO (Eur. Mol. Biol. 
Organ.) ./.11:4795-4804. 
36. Li, R.Y., F. Gaits, A. Rageb, J.M. Rageb-Thomas, and H. Chap. 1995. Ty- 
rosine  phosphorylation  of  an  SH2-containing  protein  tyrosine  phos- 
phatase is coupled to platelet thrombin receptor via pertussis toxin-sensi- 
titive  heterotrimeric  G-protein.  EMBO  (Eur.  Mol.  BioL  Organ.)  J.14: 
2519-2526. 
37. Ling, W.L.W., and D. Shields. 1996. Formation of secretory vesicles in per- 
meabilized cells: a salt extract from yeast membranes promotes budding 
of nascent secretory vesicles from the trans-Golgi network of endocrine 
cells. Biochem. J. 314:723-726. 
38. Liscovitch, M., and L.C. Cantley. 1995. Signal transduction  and membrane 
traffic: the PITP/phosphoinositide  connection. Cell. 81:659-662. 
39. Malarkey, K., C.M. Belham, A. Paul, A. Graham, A. McLees, P.H. Scott, 
and  R. Plevin. 1995. The regulation  of tyrosine  kinase signalling path- 
ways by growth factor and G-protein-coupled  receptors. Biochem. Z 309: 
361-375. 
40. Narula, N., I. McMorrow, G. Plopper, J. Doherty,  K.S. Marlin, B. Burke, 
and J.L. Stow. 1992. Identification  of a 200-kD, brefeldin-sensitive pro- 
tein on Golgi membranes. J. Cell Biol. 117:27-38. 
41. Nuoffer,  C., and W.E.  Balch. 1994. GTPases:  multifunctional  molecular 
switches regulating vesicular traffic. Annu. Rev. Biochem. 63:949-990. 
42. Ohashi,  M., and  W.B. Huttner.  1994. An elevation  of cytosolic protein 
phosphorylation  modulates  trimeric  G-protein  regulation  of secretory 
vesicle formation  from the  trans-Golg~  network.  J.  Biol.  Chem.  269: 
24897-24905. 
43. Ohashi, M., K. Jan de Vries, R. Frank, G. Snoek, V. Bankaitis, K. Wirtz, 
and W. Huttner.  1995. A role for phosphatidylinositol transfer protein in 
secretory vesicle formation. Nature (Lond.). 377:544-547. 
44. Pfeffer, S.R. 1994. Rab GTPases: master regulators of membrane traffick- 
ing. Curr.  Opin. Cell BioL 6:522-526. 
45. Pimplikar, S.W., and K. Simons. 1993. Regulation of apical transport in ep- 
ithelial cells by a Gs class of heterotrimeric  G protein.  Nature (Lond.). 
362:456--458. 
46. Pimplikar, S.W., and K. Simons. 1994. Activators of protein kinase A stim- 
ulate apical but not basolateral  transport in epithelial Madin-Darby  ca- 
nine kidney cells. J. BioL Chem. 269:19054-19059. 
47. Posner, B.I., R. Faure, J.W. Burgess, A.P. Bevan, D. Lachance, G. Zhang- 
Sun, I.G. Fantus, J.B. Ng, D.A. Hall, B.S. Lure, and A. Shaver. 1994. Per- 
oxovanadium compounds. J. Biol. Chem. 269:4596-4604. 
48. Pryde, J.G.  1994. A group of integral membrane proteins  of the rat liver 
Golgi contains a conserved protein of 100 kDa. J. Cell Sci. 107:3425-3436. 
49. Pumiglia, K.M., L.-F. Lan, C.-K. Huang, S. Burroughs, and M.B. Feinstein. 
1992. Activation of signal transduction in platelets by the tyrosine phos- 
phatase inhibitor pervanadate  (vanadyi hydroperoxide).  Biochem. J. 286: 
441-449. 
50. Randazzo, P.A., T. Terui, S. Sturch, and R.A. Kahn. 1994. The amino ter- 
minus of ADP-ribosylation  factor  (ARF) 1 is essential  for interaction 
with Gs and ARF GTPase-activating protein. J. Biol. Chem. 269:29490- 
29494. 
51. Rothman, J.E. 1994. Mechanisms of intracellular protein transport. Nature 
(Lond. ). 372:55-63. 
52. Santini, F., and J.H.  Keen.  1996. Endocytosis of activated  receptors  and 
clathrin-coated  pit formation:  deciphering  the chicken or egg relation- 
ship. J. Cell Biol. 132:1025-1036. 
53. Slack, B.E., J.  Breu,  M.A.  Petryniak,  K. Srivastava, and R.J. Wurtman. 
1995. Tyrosine phosphorylation-dependent  stimulation  of amyloid pre- 
cursor protein  secretion by the m3 muscarinic acetylcholine receptor. J. 
Biol. Chem. 270:8337-8344. 
54. Stack, J.H., B. Horazdovsky, and S.D. Emr. 1995. Receptor-mediated  pro- 
tein sorting to the vacuole in yeast: roles for a protein  kinase, a lipid ki- 
nase and GTP-binding proteins. Annu. Rev. Cell Dev. Biol. 11:1-33. 
55. Stanners, J., P.S. Kabouridis, K.L. McGuire, and C.D. Tsoukas. 1995. Inter- 
action between  G proteins  and  tyrosine  kinases upon T  cell receptor- 
CD3-mediated signalling. Z Biol. Chem. 270:30635-30642. 
56. Stoller, T.J., and D. Shields. 1988. Retrovirus-mediated  expression of pre- 
prosomatostatin:  posttranslational  processing, intracellular  storage, and 
secretion in GH3 Pituitary Cells. J. Cell Biol. 107:2087-2095. 
57. Streuli, M. 1996. Protein  tyrosine  phosphatases  in signaling. Curt.  Opin. 
Cell Biol. 8:182-188. 
58. Sun, H., and N.K. Tonks. 1994. The coordinated action of protein tyrosine 
phosphatases and kinases in cell signalling. Trends Biochem. Sci. 19:480- 
485. 
59. Trudel, S., M.R. Paquet,  and S. Grinstein.  1991. Mechanism of vanadate- 
induced  activation  of tyrosine  phosphorylation  and  of the  respiratory 
burst in HL60 cells. Biochem. J. 276:611-619. 
60. Van der Geer, P., and T. Hunter.  1994. Receptor  protein-tyrosine  kinases 
and their signal transduction pathways. Annu. Rev. Cell Biol. 10:251-337. 
61. Walton, K.M. and J.E. Dixon. 1993. Protein tyrosine phosphatases. Annu. 
Rev. Biochem. 62:101-120. 
62. Xu, H., and D. Shields. 1993. Prohormone processing in the trans-Golgi 
network: endoproteolytic  cleavage of prosomatostatin  and formation of 
nascent secretory vesicles in permeabilized  cells. J.  Cell Biol. 122:1169- 
1184. 
63. Xu, H., P. Greengard,  and S. Gandy. 1995. Regulated  formation of Golgi 
secretory vesicles containing Alzheimer  13-amyloid precursor protein. Z 
Biol. Chem. 270:23243-23245. 
Austin and Shields Vesicle Budding Requires Phosphotyrosine Metabolism  1483 